Cogent Biosciences, Inc.

Healthcare · Biotechnology · United States

Last price 31.96 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 5.55B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a rev...